Physician Search

Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives.

https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/

Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine.

https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/

Filter By:
Search by Keyword:

Displaying 1 - 1 of 1

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Melanoma

Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and
safety/tolerability of ceralasertib, when administered as monotherapy and in combination with
durvalumab in participants with unresectable or advanced melanoma and primary or secondary
resistance to PD-(L)1 inhibition.

Disease Sites: Melanoma

Phase: II

Investigator: Johnson, Douglas

NCTID: NCT05061134

Protocol No: VICCMEL2177

Learn More